An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease

The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.

Inclusion Criteria:

• Any Percutaneous Coronary Intervention, more than 3 months prior to randomization
• Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation
• Treatment with ASA

Exclusion Criteria:

• ACS, transient ischemic attack (TIA), or Stroke within the 3 months prior to randomisation
• Known concurrent disease of stroke or TIA with atrial fibrillation
• Persons who are being treated with blood clotting agents that cannot be stopped